Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris A Gentry

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The Annals of Pharmacotherapy|March 23, 2026
Variables Associated With Poor Clinical Outcomes in Patients With Serious Fluconazole Non-Susceptible <i>Candida Species</i> InfectionsChris A Gentry, Cailyn Evans, Sharanjeet Thind, et al.
The Annals of Pharmacotherapy|March 13, 2026
Predictors for the Development of Invasive Infection of Fluconazole Non-Susceptible or Echinocandin Non-Susceptible <i>Candida Species</i> Across the Veterans Health AdministrationCailyn Evans, Riley J Williams, Sharanjeet Thind, et al.
The Annals of Pharmacotherapy|March 18, 2003
Aztreonam treatment of Pasteurella multocida cellulitis and bacteremiaJamie S Winner, Chris A Gentry, Linda J Machado, et al.
Critical Care Medicine|December 4, 2008
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautionsChris A Gentry, Kristin Busse Gross, Bhanu Sud, et al.
Current Drug Safety|June 6, 2012
A multicenter evaluation of the safety of drotrecogin alfa (activated) in patients with baseline bleeding precautionsRussell J Benefield, Douglas A Drevets, Mark M Huycke, et al.
Journal of Clinical Pharmacy and Therapeutics|October 24, 2018
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infectionJennifer D Tieu, Riley J Williams, Grant H Skrepnek, et al.
American Journal of Infection Control|October 12, 2005
Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluationKimi S Vesta, Paula G Wells, Chris A Gentry, et al.
The Journal of the Oklahoma State Medical Association|November 21, 2007
Part XIII. Systemic antifungal therapyKristin H Busse, Chris A Gentry, Michael S Bronze, et al.
The Journal of Infection|January 26, 2023
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agentsChris A Gentry, Phoi Nguyen, Sharanjeet K Thind, et al.
The Annals of Pharmacotherapy|January 18, 2013
Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from homeJenny I Chen, Leonard N Slater, George Kurdgelashvili, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The Annals of Pharmacotherapy|March 23, 2026
Variables Associated With Poor Clinical Outcomes in Patients With Serious Fluconazole Non-Susceptible <i>Candida Species</i> InfectionsChris A Gentry, Cailyn Evans, Sharanjeet Thind, et al.
The Annals of Pharmacotherapy|March 13, 2026
Predictors for the Development of Invasive Infection of Fluconazole Non-Susceptible or Echinocandin Non-Susceptible <i>Candida Species</i> Across the Veterans Health AdministrationCailyn Evans, Riley J Williams, Sharanjeet Thind, et al.
The Annals of Pharmacotherapy|March 18, 2003
Aztreonam treatment of Pasteurella multocida cellulitis and bacteremiaJamie S Winner, Chris A Gentry, Linda J Machado, et al.
Critical Care Medicine|December 4, 2008
Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautionsChris A Gentry, Kristin Busse Gross, Bhanu Sud, et al.
Current Drug Safety|June 6, 2012
A multicenter evaluation of the safety of drotrecogin alfa (activated) in patients with baseline bleeding precautionsRussell J Benefield, Douglas A Drevets, Mark M Huycke, et al.
Journal of Clinical Pharmacy and Therapeutics|October 24, 2018
Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infectionJennifer D Tieu, Riley J Williams, Grant H Skrepnek, et al.
American Journal of Infection Control|October 12, 2005
Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluationKimi S Vesta, Paula G Wells, Chris A Gentry, et al.
The Journal of the Oklahoma State Medical Association|November 21, 2007
Part XIII. Systemic antifungal therapyKristin H Busse, Chris A Gentry, Michael S Bronze, et al.
The Journal of Infection|January 26, 2023
Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agentsChris A Gentry, Phoi Nguyen, Sharanjeet K Thind, et al.
The Annals of Pharmacotherapy|January 18, 2013
Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from homeJenny I Chen, Leonard N Slater, George Kurdgelashvili, et al.
Pageof 3